Orogastric and intravenous indomethacin administration to very premature neonates with patent ductus arteriosus: Population pharmacokinetics, absolute bioavailability, and treatment outcome

Therapeutic Drug Monitoring

Volumn 29, Issue 6, 2007, Pages 807-814

  Za'abi, Mohammed Al ^a   Donovan, Timothy ^b   Tudehope, David ^c   Woodgate, Paul ^c   Collie, Li An ^b   Charles, Bruce ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c MATER MOTHERS HOSPITAL   (Australia)

Author keywords

Ductus arteriosus; Indomethacin; Population pharmacokinetics; Preterm infants; Therapeutic drug monitoring

Indexed keywords

INDOMETACIN;

ARTICLE; BIRTH WEIGHT; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; GESTATIONAL AGE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PATENT DUCTUS ARTERIOSUS; PERINATAL PERIOD; PREMATURITY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; CARDIOVASCULAR AGENTS; DUCTUS ARTERIOSUS, PATENT; FEMALE; HUMANS; INDOMETHACIN; INFANT, NEWBORN; INFANT, PREMATURE; INJECTIONS, INTRAVENOUS; MALE; TREATMENT OUTCOME;

EID: 36549078271     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31815b3e13     Document Type: Article

References (41)

1. Evans N, Archer L. Postnatal circulatory adaptation in healthy term and preterm neonates. Arch Dis Child. 1990;65:24-26.
2. Narayanan M, Clyman R. Pharmacologic closure of patent ductus arteriosus in the neonate. NeoReviews. 2003;4:e215-e222.
3. Clyman RI. Patent ductus arteriosus in premature infant. In: Taeusch WH, Ballard RA, eds. Avery's Diseases of the Newborn, 7th ed. Philadelphia: WB Saunders Co; 1998:699-710.
4. Gersony W, Peckham G, Ellison R, et al. A. Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr. 1983;102:895-905.
5. Rudd P, Montanez P, Hallidie-Smith K, et al. Indomethacin treatment for patent ductus arteriosus in very low birthweight infants: double blind trial. Arch Dis Child. 1983;58:267-270.
6. Mrongovius R, Imbeck H, Wille L, et al. Variability of serumindomethacin concentrations after oral and intravenous administration to preterminfants. Eur J Pediatr. 1982;138:151-153.
7. Thalji A, Carr I, Yeh T, et al. Pharmacokinetics of intravenously administered indomethacin in premature infants. J Pediatr. 1980;97:995-1000.
8. Yaffe S, Friedman W, Rogers D, et al. The disposition of indomethacin in preterm babies. J Pediatr. 1980;97:1001-1006.
9. Brash A, Hickey D, Graham T, et al. Pharmacokinetics of indomethacin in the neonate. Relation of plasma indomethacin levels to response of the ductus arteriosus. N Engl J Med. 1981;305:67-72.
10. Wiest D, Pinson J, Gal P, et al. Population pharmacokinetics of intravenous indomethacin in neonates with symptomatic patent ductus arteriosus. Clin Pharmacol Ther. 1991;49:550-557.
11. Smyth JM, Collier PS, Darwish M, et al. Intravenous indomethacin in preterm infants with symptomatic patent ductus arteriosus. A population pharmacokinetic study. Br J Clin Pharmacol. 2004;58:249-258.
12. Clyman RI. Recommendations for the postnatal use of indomethacin: an analysis of four separate treatment strategies. J Pediatr. 1996;128:601-607.
13. Kaapa P, Lanning P, Koivisto M. Early closure of patent ductus arteriosus with indomethacin in preterm infants with idiopathic respiratory distress syndrome. Acta Paediatr Scand. 1983;72:179-184.
14. Gal P, Ransom JL, Schall S, et al. Indomethacin for patent ductus arteriosus closure. Application of serum concentrations and pharmacodynamics to improve response. J Perinatol. 1990;10:20-26.
15. Shaffer CL, Gal P, Ransom JL, et al. Effect of age and birth weight on indomethacin pharmacodynamics in neonates treated for patent ductus arteriosus. Crit Care Med. 2002;30:343-348.
16. Al-Za'abi MA, Dehghanzadeh GH, Norris RLG, et al. A rapid and sensitive microscale HPLC method for the determination of indomethacin in plasma of premature neonates with patent ductus arteriosus. J Chromatogr B. 2006;830:364-367.
17. Boeckmann A, Sheiner L, Beal S. NONMEM Users' Guide. San Francisco: NONMEM Project Group, University of California; 1999.
18. Ette EI, Williams PJ, Kim YH, et al. Model appropriateness and population pharmacokinetic modeling. J Clin Pharmacol. 2003;43:610-623.
19. Lee TC, Charles BG, Steer PA, et al. Theophylline population pharmacokinetics from routine monitoring data in very premature infants with apnoea. Br J Clin Pharmacol. 1996;41:191-200.
20. Oberbauer R, Krivanek P, Turnheim K. Pharmacokinetics of indomethacin in the elderly. Clin Pharmacokinet. 1993;24:428-434.
21. Helleberg L. Clinical pharmacokinetics of indomethacin. Clin Pharmacokinet. 1981;6:245-258.
22. Morselli PL. Clinical pharmacology of the perinatal period and early infancy. Clin Pharmacokinet. 1989;17:13-28.
23. Bhat R, Vidyasagar D, Fisher E, et al. Pharmacokinetics of oral and intravenous indomethacin in preterm infants. Dev Pharmacol Ther. 1980;1:101-110.
24. Evans M, Bhat R, Vidyasagar D, et al. A comparison of oral and intravenous indomethacin dispositions in the premature infant with patent ductus arteriosus. Pediatr Pharmacol. 1981;1:251-258.
25. So LY, Fok TF, Sung RY, et al. Preterm infants with patent ductus arteriosus: treatment with an enteral preparation of indomethacin. Ann Trop Paediatr. 1992;12:403-408.
26. Lewis IG, Harvey DP, Maxwell GM. Indomethacin therapy of patent ductus in preterm infants controlled by plasma levels. Aust Paediatr J. 1985;21:181-183.
27. Alvan G, Orme M, Bertilsson L, et al. Pharmacokinetics of indomethacin. Clin Pharmacol Ther. 1975;18:364-373.
28. Lee J, Rajadurai VS, Tan KW, et al. Randomized trial of prolonged lowdose versus conventional-dose indomethacin for treating patent ductus arteriosus in very low birth weight infants. Pediatrics. 2003;112:345-350.
29. Tammela O, Ojala R, Iivainen T, et al. Short versus prolonged indomethacin therapy for patent ductus arteriosus in preterm infants. J Pediatr. 1999;134:552-557.
30. Nakamura T, Tamura M, Kadowaki S, et al. Low-dose continuous indomethacin in early days of age reduce the incidence of symptomatic patent ductus arteriosus without adverse effects. Am J Perinatol. 2000;17:271-275.
31. Rennie JM, Cooke RW. Prolonged low dose indomethacin for persistent ductus arteriosus of prematurity. Arch Dis Child. 1991;66:55-58.
32. Rhodes PG, Ferguson MG, Reddy NS, et al. Effects of prolonged versus acute indomethacin therapy in very low birth-weight infants with patent ductus arteriosus. Eur J Pediatr. 1988;147:481-484.
33. Seyberth HW, Knapp G, Wolf D, et al. Introduction of plasma indomethacin level monitoring and evaluation of an effective threshold level in very low birth weight infants with symptomatic patent ductus arteriosus. Eur J Pediatr. 1983;141:71-76.
34. Ramsay JM, Murphy DJ, Vick GW, et al. Response of the patent ductus arteriosus to indomethacin treatment. Am J Dis Child. 1987;141:294-297.
35. Vert P, Bianchetti G, Marchal F, et al. Effectiveness and pharmacokinetics of indomethacin in premature newborns with patent ductus arteriosus. Eur J Clin Pharmacol. 1980;18:83-88.
36. Smith IJ, Goss I, Congdon PJ. Intravenous indomethacin for patent ductus arteriosus. Arch Dis Child. 1984;59:537-541.
37. Ivey HH, Kattwinkel J, Park TS, et al. Failure of indomethacin to close persistent ductus arteriosus in infants weighing under 1000 grams. Br Heart J. 1979;41:304-307.
38. Weiss H, Cooper B, Brook M, et al. Factors determining reopening of the ductus arteriosus after successful clinical closure with indomethacin. J Pediatr. 1995;127:466-471.
39. Smith GC. The pharmacology of the ductus arteriosus. Pharmacol Rev. 1998;50:35-58.
40. Momma K, Takao A. In vivo constriction of the ductus arteriosus by nonsteroidal antiinflammatory drugs in near-term and preterm fetal rats. Pediatr Res. 1987;22:567-572.
41. Moise KJ, Huhta JC, Sharif DS, et al. Indomethacin in the treatment of premature labor. Effects on the fetal ductus arteriosus. N Engl J Med. 1988;319:327-331.